Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Key Points

• Roivant CEO Eric Venker sold 200,000 shares on April 20 at an average price of $29.59 for $5.918M, reducing his stake by 10.83% to 1,647,546 shares; the trade was executed under a pre-arranged Rule 10b5-1 plan and follows two prior 200,000-share sales in February and March (600,000 shares total).
• Analysts are broadly positive with a consensus rating of “Moderate Buy” (10 Buys, 1 Hold, 1 Sell) and an average target of $30.55, while several firms have raised targets — e.g., Citigroup and Sanford Bernstein $35, Piper Sandler $40.
• Shares trade around $29.15 (50-day MA $28.14, 200-day MA $23.42) with a market cap of $20.86B and a 12-month high of $30.33, and recent volume has exceeded the stock's average.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the business's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the completion of the sale, the chief executive officer owned 1,647,546 shares in the company, valued at $48,750,886.14. This represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $28.24, for a total transaction of $5,648,000.00.
• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV traded down $0.14 on Wednesday, hitting $29.15. The company's stock had a trading volume of 8,451,804 shares, compared to its average volume of 6,063,708. The stock has a 50 day moving average of $28.14 and a 200-day moving average of $23.42. The company has a market capitalization of $20.86 billion, a price-to-earnings ratio of -24.91 and a beta of 1.20. Roivant Sciences Ltd. has a 12-month low of $10.57 and a 12-month high of $30.33.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an "outperform" rating and a $35.00 price target on the stock. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Citigroup upped their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, February 10th. Finally, Piper Sandler lifted their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an "overweight" rating in a research note on Thursday, April 16th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $30.55.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of the stock. Pictet Asset Management Holding SA raised its position in shares of Roivant Sciences by 15.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,673,233 shares of the company's stock worth $74,049,000 after buying an additional 360,797 shares during the period. Louisiana State Employees Retirement System purchased a new stake in Roivant Sciences during the first quarter valued at about $3,620,000. Fifth Third Wealth Advisors LLC increased its stake in Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after acquiring an additional 445 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Roivant Sciences by 2.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 7,076,488 shares of the company's stock worth $196,019,000 after purchasing an additional 139,376 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of Roivant Sciences by 2,651.5% in the 1st quarter. SG Americas Securities LLC now owns 640,923 shares of the company's stock worth $17,754,000 after purchasing an additional 617,629 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.